Biodock vs Revvity
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI cloud computing platform for life sciences microscopy images and NGS sequencing data management; $2.1M a16z pre-seed backed YC W21 at $750K ARR serving biotech and academic research labs.
About
Biodock is a San Francisco-based AI cloud computing platform for life sciences research — providing data management, analysis, and collaboration infrastructure specifically designed for biological research data including microscopy images, next-generation sequencing (NGS) outputs, and other large-scale biological datasets that overwhelm general-purpose cloud storage and analytics tools. Founded in 2020 and backed by Andreessen Horowitz in a pre-seed round with $2.1-2.33 million raised, plus notable angel investors from Tiger Global and Flatiron Health, Biodock (YC W21) reached $750,000 in annual revenue as of June 2025.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
About
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.